Immuneering Corporation · NASDAQ:IMRX
Immuneering — Investor Presentation (September 2026)
28 slides from Immuneering's investor presentation, September 2026
Slide 1: Engineering Longer Survival with Fewer Tradeoffs
Engineering Longer Survival with Fewer Tradeoffs September 2026 NASDAQ: IMRX
Slide 2: Forward-Looking Statements and Other Disclaimers
. FORWARD-LOOKING STATEMENTS AND OTHER DISCLAIMERS This presentation contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be con
Slide 3: Engineering for Longer Survival with Fewer Tradeoffs
E ngineering for Longer Survival with Fewer Tradeoffs Atebimetinib, the first deep cyclic ME K inhibitor | Phase 3 now enrolling in 1L pancreatic cancer (NCT07562152) 01 02 03 04 Target Technology Data Execution MEK: Achieving Its Full Deep Cyclic Inhibitors Compelling Survival A Multi-Front Strateg
Slide 4: Atebimetinib Could Unlock the Full Potential of MEK Inhibition
Atebimetinib Could Unlock the Full Potential of MEK Inhibition Our First Target: MEK $4.5B in RAS/RAF/MEK Inhibitor Sales in 2025: Pulsatile ≥IC₉₀ Inhibition with Once-Daily Oral Dosing MEK Inhibitors Drove 80%, Mostly in Combination Tumor Cell Growth Factor Pan-RAF Monotherapy, Receptor KRAS G12C I
Slide 5: Atebimetinib Could Unlock the Full Potential of MEK Inhibition
Atebimetinib Could Unlock the Full Potential of MEK Inhibition Our First Target: MEK Goal: Quadruple the Market Opportunity Pulsatile ≥IC₉₀ Inhibition with Once-Daily Oral Dosing Liabilities Strengths Tumor Cell Growth Factor Ineffective Effective Receptor 1st Generation in cancers in cancers Counte
Slide 6: Atebimetinib Combination Trials Disclosed to Date
Atebimetinib Combination Trials Disclosed to Date Indication / Setting Regimen PHASE 2 PHASE 3 REG. Collaboration / Funding 1L PDAC Atebimetinib + mGnP vs. GnP Phase 3 · Registrational Immuneering-funded 1L PDAC Atebi + mFFX Phase 2 · Efficacy Immuneering-funded Regeneron supply agreement 1L RAS-mut
Slide 7: Phase 2a 1L Pancreatic Cancer Trial Design
Phase 2a 1L Pancreatic Cancer Trial Design NCT05585320 | active, not recruiting Eligibility Full Cohort (N=55) Endpoints 320 mg QD atebimetinib + mGnP* Primary • 1L metastatic or locally advanced PDAC Median Follow Up = 11.6 months • ORR per RECIST 1.1 • No prior systemic therapy for Secondary advan
Slide 8: Phase 2a Demographics and Baseline Participant Characteristics
Phase 2a Demographics and Baseline Participant Characteristics Chung et al, Von Hoff et al, ASCO 2026 NEJM 2013 Characteristic atebimetinib + mGnP Gem/nab-Pac (GnP) Phase 2a, N=55b Phase 3, N = 431e Median age (years) 68 62 Age, ≥ 65 : < 65 years, % 62% : 38% 41% : 59% Disease status, metastatic : l
Slide 9: Compelling Survival and Tolerability in First Line Pancreatic Cancer
Compelling Survival and Tolerability in First Line Pancreatic Cancer Phase 2a | Atebimetinib (320 mg QD) + mGnP OS, N=55 — Ph2a IMRX (320 mg atebi + mGnP, N=55) Median OS (months) IMRX - Phase 2a Atebimetinib + (N=55, atebi + mGnP) mGnP (N=55) 17.3 OS Probability | Only 2 categories of TRAE grade ≥3
Slide 10: Consistent Separation from Standard of Care Gem/nab-Pac
Consistent Separation from Standard of Care Gem/nab-Pac (GnP) in First Line Pancreatic Cancer Atebimetinib (320 mg QD) + mGnP OS, N=55 — Ph2a IMRX (320 mg atebi + mGnP, N=55) Median OS IMRX - Phase 2a (months) OS Probability (N=55, atebi + mGnP) Atebimetinib + | mGnP (N=55) 17.3 GnP — Ph3 MPACT (Gem
Slide 11: Consistent Separation from Additional Standard of Care Options
Consistent Separation from Additional Standard of Care Options in First Line Pancreatic Cancer — Ph2a IMRX (320 mg atebi + mGnP, N=55) Median OS IMRX - Phase 2a (months) (N=55, atebi + mGnP) OS Probability Atebimetinib + | mGnP (N=55) 17.3 GnP — Ph3 NAPOLI-3 (NALIRIFOX) (MPACT) 8.5 — Ph3 PRODIGE (FO
Slide 12: Consistent Separation from Standard of Care on Additional Endpoints
Consistent Separation from Standard of Care Gem/nab-Pac Benchmarks on Additional Endpoints Atebimetinib + mGnP GnP (N = 55) (MPACT) Median OS 17.3 8.5 (months) [11.2, NR] Median PFS 8.3 5.5 (months) [5.9, 9.6] ORR* 36% 23% DCR* 82% 48% Participants weight stable or Primary Endpoint for Phase 3 trial
Slide 13: Overall Response Rate (ORR) and Disease Control Rate (DCR)
Overall Response Rate (ORR) and Disease Control Rate (DCR) Atebimetinib (320 mg QD) + mGnP Overall Response (ORR) & Disease Control (DCR) Rates Atebimetinib + mGnP Ph 2a 1L PDAC ORR 36% (18/50) DCR 82% (41/50) Prior Phase 3 Benchmark Overall Response (ORR) & Disease Control (DCR) Rates MPACT Pivotal
Slide 14: Deepening Durable Tumor Responses Over Time Observed
Deepening Durable Tumor Responses Over Time Observed Atebimetinib (320 mg QD) + mGnP RECIST SLD (% change) = refractory to treatment combination (N=6, on treatment = 0) Months = stabilized with eventual or potential escape (N=11, on treatment = 0) (from screening scan) = stabilized with durable or d
Slide 15: Atebimetinib (320 mg) + mGnP Safety: Treatment Related Adverse Events
Atebimetinib (320 mg) + mGnP Safety: Treatment Related Adverse Events TRAE (related to any drug) Any Grade Grade ≥3 Safety Highlights Fatigue 29 (53%) 1 (2%) Nausea 25 (45%) 0 Anaemia 23 (42%) 9 (16%) Rash 20 (36%) 3 (5%) • Grade ≥3 Anemia and Neutropenia occurred Diarrhea 20 (36%) 0 in ≥10% of part
Slide 16: MAPKeeper 301: Global Randomized Phase 3 Pivotal Trial Underway
MAPKeeper 301: Global Randomized Phase 3 Pivotal Trial Underway NCT07562152 | recruiting Participant Population: First-line (1L) metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Primary Endpoints N=255 Atebimetinib + mGnP1 OS Secondary Endpoints • First line (1L) PDAC R PFS • Metastatic setting 1:
Slide 17: Upcoming Milestones
Upcoming Milestones Multiple anticipated catalysts across distinct programs, funding expected into 2029 2026 2027 2028 2H 20 26 M id-20 27 M id-20 2 8 First patient dosed Begin IND-enabling studies Topline readout Phase 2: Atebimetinib + anti-PD-1 (cemiplimab) in non-small cell lung cancer Next DCI
Slide 18: Engineering for Longer Survival with Fewer Tradeoffs
E ngineering for Longer Survival with Fewer Tradeoffs Atebimetinib, the first deep cyclic ME K inhibitor | Phase 3 now enrolling in 1L pancreatic cancer (NCT07562152) 01 02 03 04 Target Technology Data Execution MEK: Achieving Its Full Deep Cyclic Inhibitors Compelling Survival A Multi-Front Strateg
Slide 19: Appendix
Appendix 19 © Immuneering All Rights Reserved.
Slide 20: 27+ Months Progression Free Survival in Third Line Pancreatic Cancer
27+ Months Progression Free Survival in Third Line Pancreatic Cancer Patient Treated With Atebimetinib Monotherapy in Phase 1 Baseline 1L 2L 3L SLD = Gem/Cis/nab- 18.6 cm FOLFIRINOX Pac Atebimetinib PR BOR = PD BOR = PD BOR = PR ✓ % change in SLD KE Y CLINI CAL OUT COME S 27 months −85% on treatment
Slide 21: Atebimetinib + mFFX Case Study: Complete Resolution of Liver Metastasis
Atebimetinib + mFFX Case Study: Observed Durability and Tolerability with Complete Resolution of Liver Metastasis Ongoing Phase 2 Case Study Atebimetinib + mFFX (1L PDAC; Phase 2) (1L Metastatic PDAC) RECIST SLD (% change) • 1st Line (1L): Atebi + mFFX (BOR = CR) * o 71-year-old female o >9 mo. on a
Slide 22: Favorable Safety Results Observed for Monotherapy Atebimetinib in 2L PDAC
Favorable Safety Results Observed for Monotherapy Atebimetinib in 2L PDAC Patients on atebimetinib monotherapy have described feeling almost like their pre-diagnosis selves – a truly significant outcome for individuals battling such a debilitating cancer. – Atebi Investigator Safety: Phase 2a Monoth
Slide 23: Atebimetinib Monotherapy Established Initial Activity, Durability, and Tolerability
Atebimetinib monotherapy established initial activity, durability, and tolerability Molecular rationale for combination MIA PaCa-2: Human PDAC Xenograft Copy of 125_Fig-Data: TV (mm3) - ALL groups: IMM-1-104 at 125 mpk BID Phase 1: ctDNA Monotherapy atebimetinib 3500 Key Resistance Pathways: 3250 at
Slide 24: Immuneering's Deep Cyclic Inhibitor Technology
Immuneering’s Deep Cyclic Inhibitor Technology: Engineering for Longer Survival with Fewer Tradeoffs Immuneering’s Deep Cyclic Inhibitor Technology Pulsatile ≥IC₉₀ Inhibition with Once-Daily Oral Dosing Conventional Wisdom: Chronic Inhibitors Healthy cells dose IC9₀ 1. Tolerability IC₅₀ IC₅₀ Provide
Slide 25: Atebimetinib in the MEK Inhibitor Landscape
Atebimetinib in the MEK Inhibitor Landscape CRAF-bypass resistant pMEK decreases in RAS-mutant cells Second-generation MEKi Third-generation MEKi (DCI) Avutometinib ● Atebimetinib Chronic inhibition Deep Cyclic Inhibition (DCI) Long t½, frequent dosing, or slow off-rate Short t½, fast off-rate, and
Slide 26: Mechanisms Well-Established to Improve Survival
3 Mechanisms Well-Established to Improve Survival Preserving Body Mass Shrinking Tumors Minimizing Side Effects (Countering Cachexia) Atebimetinib+ Disease Control Rate 84% of patients stable Only 2 categories of Grade mGnP - Clinical (DCR) = 82% or gain weight 3+ AEs in ≥10% of patients Evidence We
Slide 27: MAPKeeper 301 Execution
MAPKeeper 301 Execution “There is an urgent need for MAPKeeper 301 Locations new first-line treatment options that can improve treatment outcomes by augmenting survival and improving quality of life. The MAPKeeper 301 trial evaluating atebimetinib with standard of care therapy represents an exciting
Slide 28: Different 1L PDAC Patients Make Different Choices
Different 1L PDAC Patients Make Different Choices CPI monotherapy, 1% Other chemotherapy PARP irinotecan liposome combinations, 4% inhibitors or injection-containing FOLFIRI, 1% other targeted regimen, 2% therapies, 0% capecitabine/5-FU, 2% "When the field has FOLFOX, 4% more than one effective firs